ArticleFrontiers in immunology2020
Mangiferin Attenuates LPS/D-GalN-Induced Acute Liver Injury by Promoting HO-1 in Kupffer Cells.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Honokiol Ameliorates LPS/D-GalN-Induced Acute Liver Failure via Activation of SIRT3/AMPK and Keap1/Nrf2/HO-1 Signaling and Inhibition of the NF-κB/NLRP3 Inflammasome Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives.Journal of medicinal chemistry · 2026Review
- Unlocking Mangiferin: A Therapeutic Candidate Revolutionizing Liver Disease Therapy.Nutrients · 2025Review
- Isorhamnetin protects against D-GalN/LPS-induced acute liver injury in mice through anti-oxidative stress, anti-inflammation, and anti-apoptosis.BMC complementary medicine and therapies · 2025Article
- Hydroxytyrosol Alleviates Acute Liver Injury by Inhibiting the TNF-α/PI3K/AKT Signaling Pathway via Targeting TNF-α Signaling.International journal of molecular sciences · 2024Article
- Enhancing hepatoprotective action: oxyberberine amorphous solid dispersion system targeting TLR4.Scientific reports · 2024Article
- Review
- Mangiferin Ameliorates CClJournal of inflammation research · 2024Article
- Tomatidine Alleviates Intervertebral Disc Degeneration by Activating the Nrf2/HO-1/GPX4 Signaling Pathway.Drug design, development and therapy · 2024Article
- Mangiferin for the Management of Liver Diseases: A Review.Foods (Basel, Switzerland) · 2023Review
- Mangiferin: the miraculous xanthone with diverse pharmacological properties.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Capsaicin protects against septic acute liver injury by attenuation of apoptosis and mitochondrial dysfunction.Heliyon · 2023Article
- Chinese herbal medicine and active ingredients for diabetic cardiomyopathy: molecular mechanisms regulating endoplasmic reticulum stress.Frontiers in pharmacology · 2023Review
- Protective effects of glutamine on lipopolysaccharide/D-galactosamine-induced fulminant hepatitis in mice.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Effects of Herbs and Derived Natural Products on Lipopolysaccharide-Induced Toxicity: A Literature Review.Oxidative medicine and cellular longevity · 2023Review
- Sodium Hydrosulfide Modification of Mesenchymal Stem Cell-Exosomes Improves Liver Function in CCL4-Induced Hepatic Injury in Mice.Reports of biochemistry & molecular biology · 2023Article
- Hepatocyte-Conditional Knockout of Phosphatidylethanolamine Binding Protein 4 Aggravated LPS/D-GalN-Induced Acute Liver InjuryFrontiers in immunology · 2022Article
- Article
- HBx facilitates ferroptosis in acute liver failure via EZH2 mediated SLC7A11 suppression.Journal of biomedical science · 2021Article
- Acute Effects of a Polyphenol-Rich Leaf Extract ofNutrients · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver injury and its terminal phase, hepatic failure, trigger a series of complications, including hepatic encephalopathy, systematic inflammatory response syndrome, and multiorgan failure, with relatively high morbidity and mortality. Liver transplantation is the ultimate intervention, but the shortage of donor organs has limited clinical success. Mangiferin (MF), a xanthone glucoside, has been reported to have excellent anti-inflammatory efficacy. Here, a lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury mouse model was established to investigate the protective role of MF and the underlying mechanisms of action. Pretreatment with MF improved survival, decreased serum aminotransferase activities, and inhibited hepatic TNF-α production in LPS/D-GalN-challenged mice. Through Kupffer cell (KC) deletion by GdCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.